|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | challenges of advanced hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC) is an aggressive malignancy,resulting as the third cause of death by cancer each year. The management of patients with HCC is complex,as both the tumour stage and any underlying liver disease must be considered conjointly. Although surveillance by imaging,clinical and biochemical parameters is routinely performed,a lot of patients suffering from cirrhosis have an advanced stage HCC at the first diagnosis. Advanced stage HCC includes heterogeneous groups of patients with different clinical condition and radiological features and sorafenib is the only approved treatment according to Barcelona Clinic Liver Cancer. Since the introduction of sorafenib in clinical practice,several phase Ⅲ clinical trials have failed to demonstrate any superiority over sorafenib in the frontline setting. Locoregional therapies have also been tested as first line treatment,but their role in advanced HCC is still matter of debate. No single agent or combination therapies have been shown to impact outcomes after sorafenib failure. Therefore this review will focus on the range of experimental therapeutics for patients with advanced HCC and highlights the successes and failures of these treatments as well as areas for future development. Specifics such as dose limiting toxicity and safety profile in patients with liver dysfunction related to the underlying chronic liver disease should be considered when developing therapies in HCC. Finally,robust validated and reproducible surrogate end-points as well as predictive biomarkers should be defined in future randomized trials. | Stefano Colagrande Andrea L Inghilesi Sami Aburas Gian G Taliani Cosimo Nardi Fabio Marra | 2016 | World Journal of Gastroenterology2016，22，34： | 19 |
| 2 | Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development显示文摘 | Maria Assunta Zocco Enrico Di Stasio Raimondo De Cristofaro Marialuisa Novi Maria Elena Ainora Francesca Ponziani Laura Riccardi Stefano Lancellotti Angelo Santoliquido Roberto Flore Maurizio Pompili Gian Lodovico Rapaccini Paolo Tondi Giovanni Battista G | 2009 | Journal of Hepatology2009，，4： | 5 |
| 3 | Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer显示文摘AIM To investigate the impact of thymidylate synthase(TYMS), KRAS and BRAF in the survival of metastatic colorectal cancer(m CRC) patients treated with chemotherapy. METHODS Clinical data were collected retrospectively from records of consecutive patients with m CRC treated with fluoropyrimidine-based chemotherapy from 1/2005 to 1/2007. Formalin-fixed paraffin-embedded tissues were retrieved for analysis. TYMS genotypes were identified with restriction fragment analysis PCR, while KRAS and BRAF mutation status was evaluated using real-time PCR assays. TYMS gene polymorphisms of each of the 3' untranslated region(UTR) and 5'UTR were classified into three groups according to the probability they have for high, medium and low TYMS expression(and similar levels of risk) based on evidence from previous studies. Univariate and multivariate survival analyses were performed.RESULTS The analysis recovered 89 patients with m CRC(46.1% de novo metastatic disease and 53.9% relapsed). Of these, 46 patients(51.7%) had colon cancer and 43(48.3%) rectal cancer as primary. All patients were treated with fluoropyrimidine-based chemotherapy(5FU or capecitabine) as single-agent or in combination with irinotecan or/and oxaliplatin or/and bevacizumab. With a median follow-up time of 14.8 mo(range 0-119.8), 85 patients(95.5%) experienced disease progression, and 63 deaths(70.8%) were recorded. The 3-year and 5-year OS rate was 25.4% and 7.7% while the 3-year progression-free survival rate was 7.1%. Multivariate analysis of TYMS polymorphisms, KRAS and BRAF with clinicopathological parameters indicated that TYMS 3'UTR polymorphisms are associated with risk for disease progression and death(P < 0.05 and P < 0.03 respectively). When compared to tumors without any del allele(genotypes ins/ins and ins/loss of heterozygosity(LOH) linked with high TYMS expression) tumors with del/del genotype(low expression group) and tumors with ins/del or del/LOH(intermediate expression group) have lower risk for disease progression(HR = 0.432, 95%CI: 0.198-0.946, P < 0.04 and HR = 0.513, 95%CI: 0.287-0.919, P < 0.03 respectively) and death(HR = 0.366, 95%CI: 0.162-0.827, P < 0.02 and HR = 0.559, 95%CI: 0.309-1.113, P < 0.06 respectively). Additionally,KRAS mutation was associated independently with the risk of disease progression(HR = 1.600, 95%CI: 1.011-2.531, P < 0.05). The addition of irinotecan in 1st line chemotherapy was associated independently with lower risk for disease progression and death(HR = 0.600, 95%CI: 0.372-0.969, P < 0.04 and HR = 0.352, 95%CI: 0.164-0.757, P < 0.01 respectively).CONCLUSION The TYMS genotypes ins/ins and ins/LOH associate with worst prognosis in m CRC patients under fluoropyrimidine-based chemotherapy. Large prospective studies are needed for validation of our findings. | Anastasios Ntavatzikos Aris Spathis Paul Patapis Nikolaos Machairas George Peros Stefanos Konstantoudakis Danai Leventakou Ioannis G Panayiotides Petros Karakitsos Anna Koumarianou | 2017 | World Journal of Gastroenterology2017，23，32： | 4 |
| 4 | Dabigatran,rivaroxaban,and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation:An updated metaanalysis显示文摘BACKGROUND Most of the randomized clinical trials that led to the wide use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation(AF)originated from western countries.AIM To systematically review and quantitatively synthesize the real-world data regarding the efficacy and safety of dabigatran,rivaroxaban,and apixaban compared to warfarin for stroke prevention in Asian patients with non-valvular AF.METHODS Medline,Cochrane,and ClinicalTrial.gov databases were reviewed.A randomeffect model meta-analysis was used and I-square was utilized to assess the heterogeneity.The primary outcome was ischemic stroke.The secondary outcomes were all-cause mortality,major bleeding,intracranial hemorrhage,and gastrointestinal bleeding.RESULTS Twelve studies from East Asia or Southeast Asia and 441450 patients were included.Dabigatran,rivaroxaban,and apixaban were associated with a significant reduction in the incidence of ischemic stroke[hazard ratio(HR)=0.78,95%confidence interval(CI):0.65-0.94;HR=0.79,95%CI:0.74-0.85,HR=0.70,95%CI:0.62-0.78;respectively],all-cause mortality(HR=0.68,95%CI:0.56-0.83;HR=0.66,95%CI:0.52-0.84;HR=0.66,95%CI:0.49-0.90;respectively),and major bleeding(HR=0.61,95%CI:0.54-0.69;HR=0.70,95%CI:0.54-0.90;HR=0.58,95%CI:0.43-0.78;respectively)compared to warfarin.CONCLUSION Dabigatran,rivaroxaban,and apixaban appear to be superior to warfarin in both efficacy and safety in Asians with non-valvular AF. | Wei-Jia Li Paraschos Archontakis-Barakakis Leonidas Palaiodimos Dimitrios Kalaitzoglou Lazaros Tzelves Apostolos Manolopoulos Yu-Chiang Wang Stefanos Giannopoulos Robert Faillace Damianos G Kokkinidis | 2021 | World Journal of Cardiology2021，13，4： | 3 |
| 5 | Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development显示文摘 | Maria Assunta Zocco Enrico Di Stasio Raimondo De Cristofaro Marialuisa Novi Maria Elena Ainora Francesca Ponziani Laura Riccardi Stefano Lancellotti Angelo Santoliquido Roberto Flore Maurizio Pompili Gian Lodovico Rapaccini Paolo Tondi Giovanni Battista G | 2009 | Journal of Hepatology2009，，4： | 2 |
| 6 | Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial显示文摘 | Viviana Galimberti Bernard F Cole Stefano Zurrida Giuseppe Viale Alberto Luini Paolo Veronesi Paola Baratella Camelia Chifu Manuela Sargenti Mattia Intra Oreste Gentilini Mauro G Mastropasqua Giovanni Mazzarol Samuele Massarut Jean-Rémi Garbay Janez Zgajn | 2013 | Lancet Oncology2013，，4： | 2 |
| 7 | The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life显示文摘 | Stefano Romeo Federica Sentinelli Valentina M Cambuli Michela Incani Tiziana Congiu Vanessa Matta Sabrina Pilia Isabel Huang-Doran Efisio Cossu Sandro Loche Marco G Baroni | 2010 | Journal of Hepatology2010，，2： | 1 |
| 8 | Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD显示文摘 | Di Stefano A Caramori G Oates T | 2002 | Eur Respir J2002，20，3： | 1 |
| 9 | Chemokine re- ceptor CCR5 expression in conjunctival epithelium of pa- tients with dry eye syndrome 显示文摘 | ABHA G MARTA S STEFANO B REZA D | 2006 | Arch Ophthalmol2006，124，5： | 1 |
| 10 | Channel Estimation and Physical Layer Adaptation Techniques for Satellite Networks Exploiting Adaptive Coding and Modulation显示文摘 | Stefano C Riccardo D G Rita R | 2008 | International Journal of Satellite Communications and Networking2008，26，2： | 1 |
| 11 | Diffusion-weighted MR imaging in the evaluation of renal tumours显示文摘 | Squillaci E Manenti G Di Stefano F | 2004 | J Exp Clin Cancer Res2004，23，1： | 1 |
| 12 | Successful multimoclal treatment of a breast cancer patient with a recurrence invading the chest wall显示文摘 | Corrado G di Stefano A Salutari V | 2011 | J Chemother2011，23，1： | 1 |
| 13 | Percutaneous sonographically guided saline-enhanced radiofrequency ablation of hepatocellular carcinoma显示文摘 | GIORGIO A TARANTINO L de STEFANO G | 2003 | AJR2003，181，2： | 1 |
| 14 | Liver targeting of an- tiviral nucleoside analogues through the asialoglycoprotein receptor 显示文摘 | FLUME L DI STEFANO G BUSI C | 1997 | J Viral Hepat1997，4，6： | 1 |
| 15 | Electroluminescence of silicon nanocrystals in MOS structures显示文摘 | Franzò G Irrera A Moreira E C Miritello M Iacona F Sanfilippo D Di Stefano G Fallica P G Priolo F | | 0，，： | 1 |
| 16 | Association of in- creased CCL5 and CXCL7 ehemokine expression with neutrophil activation in severe stable COPD 显示文摘 | Di Stefano A Caramori G Gnemmi I | 2009 | Thorax2009，64，11： | 1 |
| 17 | Chemokines and chemokine receptors blockers as new drugs for the treatment of chronic obstructive pulmonary disease显示文摘 | Caramori G Di Stefano A Casolari P | 2013 | Curr Med Chem2013，20，35： | 1 |
| 18 | Applications of liquid chromatography- mass spectrometry for food analysis 显示文摘 | Stefano VD Avellone G Bongiorno D | 2012 | Journal of Chromatography A2012，1259，： | 1 |
| 19 | The echo-g uided interstitial laser photocoagulation of malignant Liver tumors显示文摘 | Tarantinol De stefano G | 2000 | Radiol Med(Torino)2000，99，4： | 1 |
| 20 | CD8^+T Lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease显示文摘 | Saetta M Di Stefano A Turato G | 1998 | Am J Respir Crit Care Med1998，157，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员